Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

Metastatic breast cancer market is projected to grow significantly through 2035, driven by rising cases, treatment advances, and expanding R&D investments.

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get? Hopefully a new standard of care for the aggressive disease ...

Gilead Sciences (NASDAQ:GILD) announced Saturday that its antibody-drug conjugate Trodelvy, in combination with Merck’s (NYSE ...

Cell division cycle 20 homolog (CDC20) is a key regulatory protein involved in mitotic progression. Aberrant overexpression of CDC20 has been implicated in tumorigenesis and is associated with poor ...